THC and CBD are both compounds found in the cannabis plant, but they produce very different effects in your body. THC is the one that gets you high. CBD does not. That single distinction drives most of the differences people care about, from how each compound feels to whether it shows up on a drug test. The reason comes down to how they interact with receptors in your brain.
Why THC Gets You High and CBD Doesn’t
Your body has a network of cannabinoid receptors, the most important being CB1 (concentrated in the brain and central nervous system) and CB2 (found mostly in the immune system). THC binds tightly to CB1 receptors, activating them directly. This activation is what produces the high: euphoria, altered perception of time, relaxation, and changes in sensory experience. THC’s binding affinity to human CB1 receptors is roughly 25 nanomoles, meaning it latches on at very low concentrations.
CBD barely touches those same receptors. Its binding affinity is measured in the thousands of nanomoles, roughly 100 times weaker. At typical doses, CBD simply doesn’t activate CB1 receptors the way THC does. Instead, CBD works as a negative allosteric modulator of CB1, meaning it can actually change the shape of the receptor and dampen its response to other compounds. CBD is technically psychoactive in the sense that it can influence mood and anxiety, but it is not intoxicating. You won’t feel impaired, euphoric, or “stoned.”
Side Effects Compared
THC’s side effects reflect its direct action on the brain. Common effects include light-headedness, floating sensations, difficulty concentrating, mental confusion, impaired short-term memory, and a distorted sense of time. At higher doses or in sensitive individuals, THC can trigger anxiety, paranoia, hallucinations, and full-blown panic attacks. Cannabis users sometimes call this “greening out,” which involves sweating, nausea, racing heart, and an overwhelming fear that something is seriously wrong.
CBD’s side effect profile is far milder. It does not cause cognitive impairment on its own. The most commonly reported issues are drowsiness, decreased appetite, diarrhea, and fatigue. These tend to be mild, temporary, and most likely at higher doses (around 400 mg per day or more over several weeks). For most people taking typical consumer doses, CBD produces no noticeable side effects at all.
FDA-Approved Medical Uses
Both compounds have made it into prescription medications, though for very different conditions. The FDA has approved Epidiolex, a purified CBD medication, for treating seizures in patients one year and older with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. These are severe forms of epilepsy that often resist other treatments.
On the THC side, the FDA has approved Marinol and Syndros, which contain a synthetic version of THC called dronabinol. These are prescribed for loss of appetite and weight loss in AIDS patients. A related drug, Cesamet, contains a synthetic compound with a chemical structure similar to THC and is also FDA-approved. Beyond these specific approvals, both THC and CBD are used in various state-legal medical cannabis programs for a broader range of conditions, though that use isn’t regulated at the federal level the same way.
How They Work Together
When THC and CBD are consumed together, CBD appears to soften some of THC’s harsher effects. Part of this happens at the receptor level: CBD’s role as a negative allosteric modulator of CB1 receptors means it can reduce how strongly THC activates those receptors. There’s also a pharmacokinetic component. CBD inhibits certain liver enzymes in the cytochrome P450 family, which slows the conversion of THC into 11-OH-THC, a metabolite that is actually more potent and more psychoactive than THC itself.
This is sometimes called the “entourage effect,” and cannabis products with a balance of both THC and CBD (often labeled as Type II chemovars) are thought to offer therapeutic benefits with fewer adverse effects like anxiety and paranoia. That said, reliable scientific evidence for a true synergy between cannabinoids and terpenes at the receptor level hasn’t been established yet. The moderating influence of CBD on THC’s effects is better supported than the broader entourage claims.
Drug Testing
Standard workplace drug tests screen for THC metabolites, not CBD. Pure CBD will not trigger a positive result. However, many CBD products are not pure CBD. Hemp-derived products can legally contain up to 0.3% THC in the United States, and some retail products contain more THC than their labels claim. In a controlled study, participants who vaped CBD-dominant cannabis (which contained small amounts of THC) all had detectable THC metabolites in their urine. Three out of 18 participants produced levels above the 15 ng/mL federal workplace confirmation cutoff, and two of those samples also exceeded the initial 50 ng/mL screening threshold.
Importantly, the study found no evidence that CBD converts into THC inside the body after being inhaled or swallowed. The positive drug tests came from THC that was already present in the product, not from any chemical transformation of CBD. If you face drug testing and use CBD products, the risk depends entirely on how much THC is actually in what you’re taking. Products labeled “broad spectrum” or “CBD isolate” carry less risk than full-spectrum products, but mislabeling is common in an under-regulated market.
Legal Status in the United States
The legal distinction between THC and CBD hinges on a single number: 0.3%. The 2018 Farm Bill defined hemp as any part of the cannabis plant containing no more than 0.3% delta-9 THC on a dry-weight basis. Products that meet this threshold are federally legal, which is why CBD derived from hemp is widely sold across the country. Cannabis plants with more than 0.3% THC remain classified as marijuana under federal law, though many states have their own medical or recreational cannabis programs that permit higher-THC products.
This 0.3% line creates some quirks. Products with very small amounts of THC, like certain full-spectrum CBD oils, are technically legal at the federal level even though they contain a psychoactive compound. And some manufacturers have exploited the Farm Bill’s language to sell concentrated THC products (including delta-8 THC) derived from legal hemp, leading to ongoing legal challenges at the state level.
Safety and Overdose Risk
Neither THC nor CBD poses a realistic risk of fatal overdose when used alone. A large-scale review of deaths associated with cannabis use in England from 1998 to 2020 found that cannabis toxicity was cited as the cause in just one case out of 3,455 cannabis-related deaths examined. The vast majority involved other drugs (96% of cases involved polydrug use), and traumatic injury, not toxicity, was the leading cause of death in the small number of cases where cannabis was the only substance detected.
That doesn’t mean THC is without risk. The same analysis found that cardiac complications were the most commonly cited physiological cause of death in cannabis-related cases. People with existing heart conditions face a higher level of concern. THC also impairs coordination and judgment, which raises the danger in situations involving driving or physical hazards. CBD, by contrast, does not produce impairment and has not been associated with similar acute safety concerns.